IGF-1 DES

Structure: IGF-1 with the N-terminal tripeptide Gly-Pro-Glu removed, leaving a 67 amino acid peptide. That tripeptide is what IGF binding proteins grip, so removing it drops IGFBP affinity by orders of magnitude. The practical consequence is that DES circulates free rather than in the long-lived ternary complex, which makes it several times more potent than native IGF-1 in cell assays and correspondingly faster to disappear.

Dosage:

• Common protocols: 50-100mcg per injection, occasionally up to 150mcg, once daily.
• Timing: immediately post-workout is the near-universal convention, on the logic that receptor availability and blood flow are highest then.
• Duration: typically run in 4 to 6 week blocks. Longer runs are not better documented, just longer.
• These numbers come from user practice, not trials. There is no established human dose for DES(1-3)IGF-1 for muscle growth.

Administration:

• SubQ or IM, insulin syringe (29-31g)
• Reconstitute with bacteriostatic water; the peptide is unstable, so keep it refrigerated and use within a few weeks
• Do not dose fasted or before cardio. The hypoglycaemia risk is front-loaded into the first hour, which is precisely the window people train in.

Key Notes:

• The site-specific growth claim is largely unproven. The pitch is that because DES clears so fast, injecting it into a lagging muscle grows that muscle preferentially. The short half-life is real, but a peptide injected into muscle still enters the circulation, and no human study has shown preferential hypertrophy of the injected muscle. The rodent work usually cited involved direct infusion models that do not translate to a post-workout shot in the delt. Treat localised growth as a hypothesis people find appealing, not a demonstrated effect.
• DES versus LR3 is a genuine fork, not a marketing distinction. IGF-1 LR3 was engineered to evade IGFBPs and resist clearance, so it produces systemic, day-long receptor activation. DES evades IGFBPs but clears immediately. LR3 gives you sustained systemic exposure with the proliferative and hypoglycaemic concerns that come with it; DES gives you a brief spike. Neither is the "safe" version.
• Hypoglycaemia is the acute danger. At supraphysiological concentrations IGF-1 cross-reacts with the insulin receptor. The short duration limits how long you are exposed, but it does not prevent a hypoglycaemic episode inside that window. Have carbohydrate available.
• The long-run concern with any IGF-1 receptor agonist is proliferative signalling, since IGF-1 is a growth factor for normal and abnormal tissue alike. This is a theoretical risk that has not been quantified for intermittent DES use, which is another way of saying nobody has looked.
• Sourcing quality is poor. DES is a 67 amino acid protein requiring correct folding and disulfide bonding. Underdosed, misfolded, or entirely mislabelled vials are common, and there is no way to detect this from the injection or from a blood test.
• Usually run alongside Growth Hormone or an oral secretagogue like MK-677 rather than instead of them, since those raise endogenous IGF-1 systemically while DES is used as an acute pulse.

Bloodwork Monitoring:

• Glucose: the marker that matters most. Fasting glucose gives you the baseline; a glucometer around training gives you the information that actually protects you.
• HbA1c, Insulin and HOMA-IR: run these before starting and every 8 to 12 weeks, particularly if you are also using GH or exogenous insulin. The combination is where people get into trouble.
• IGF-1: worth a baseline, but understand its limits here. A normal serum IGF-1 on DES does not mean the compound is inactive, and a rising IGF-1 usually reflects your GH use rather than the DES. You cannot titrate DES by IGF-1 the way you can titrate GH.
• ALT and AST: no specific hepatic signal, but include them in the standard panel.
• No hormonal panel changes are needed on account of DES itself. It is not suppressive and does not aromatise.